Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 29, 2005 Chris Mallon	Market Contractions: Ouch! Accelerating inflation and rising interest rates are prepared to wreak havoc on growth stocks.
The Motley Fool March 18, 2009 Brian Orelli	Merck Pummels Pfizer One of these acquisitions is not like the other.
Financial Planning December 1, 2005	Are Equities Undervalued? Given the risks that exist, analysts aren't planning to overweight equities at this time. But a decline in prices could make a compelling opportunity for a tactical overweight in stocks.
The Motley Fool March 23, 2011 Todd Wenning	Dividend Report Card: Pfizer Investors considering Pfizer as a dividend play should decide if the combination of 4% current yield and low- to mid-single-digit dividend growth potential is a better deal than other pharmaceutical shares are offering.
The Motley Fool August 26, 2010 Jordan DiPietro	Pfizer's Dividends May Not Last Forever Pfizer, which operates in the pharmaceuticals industry, currently pays a dividend of 4.5%. But what's more important than the dividend itself is Pfizer's ability to keep that that cash rolling.
The Motley Fool January 26, 2009 Brian Orelli	Deja Vu All Over Again There's hardly anything to like about Pfizer's deal to buy Wyeth. This is what got Pfizer into its problem in the first place.
The Motley Fool February 28, 2005 Salim Haji	Why Value Trumps Growth Growth vs. value: This author works it out and comes up with a definitive answer. Obviously, the best possible investment is a combination -- buying a growth stock at a discount to intrinsic value.
The Motley Fool August 30, 2010 Ilan Moscovitz	Pfizer: Dividend Dynamo or Disaster? The stability and growth of Pfizer's dividend will depend on its ability to continue to develop and grow its pipeline of drugs and successfully integrate Wyeth.
The Motley Fool January 24, 2009 Alex Dumortier	Slam-Dunk Investment TIPS for 2009 There is a lesson here about Treasury Inflation-Protected Securities, TIPS, for all investors who wish to protect their assets -- even those who consider themselves purely stock investors.
The Motley Fool February 3, 2010 Brian Orelli	Wyeth Can't Save Pfizer Not much earnings growth, but the price is right.
The Motley Fool August 22, 2005 Richard Gibbons	Putting a Price on Tomorrow's Dollar Here's one way to calculate the value of any stock.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool April 27, 2007 Joe Magyer	The Weekly Dividend 'Twas a wonderful week to be a yield piggy. ExxonMobil... Procter & Gamble... IBM... etc.
The Motley Fool October 8, 2004 Whitney Tilson	Blue-Chip Bargains? Sifting through beaten-down stocks may yield some good investments. But be careful, most of these stocks are that way for a reason.
The Motley Fool September 2, 2010 Anand Chokkavelu	Is Pfizer Stock Cheap Right Now? If you find Pfizer's numbers compelling, continue your due diligence.
The Motley Fool December 13, 2011 Brian Orelli	Dividend? Buyback? Here's How to Get Both. But will there be enough to replenish the pipeline?
The Motley Fool September 15, 2006 Nathan Parmelee	Dividends: Back to Basics Investors, it's back to school time. Here's your guide on the basics of dividends.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
The Motley Fool June 11, 2008 Brian Orelli	Dueling Fools: Pfizer Bull The bullish opinion on Pfizer is that this may be the best time to buy this stock.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool May 3, 2006 Selena Maranjian	When Dividends Are Dicey A hefty dividend yield isn't always something investors can count on.
The Motley Fool September 30, 2010 Brian Orelli	Chief Justice Roberts Sold Pfizer. Should You? Maybe, but not for the same reason.
The Motley Fool February 20, 2010 Selena Maranjian	My Big Fat Dividends Stocks like these can plump up your portfolio. Stocks like Pfizer, Nokia, and Bristol-Myers Squibb can offer good yields.
The Motley Fool January 27, 2004 David Forrest	Valuing the Biggest and the Best Some old-school insight into the new economy stocks.
The Motley Fool March 7, 2007 Anders Bylund	Finding True Value: Dividend Discount Another model fits awkwardly on Texas Instruments, but the lessons learned are valuable to investors nevertheless.
The Motley Fool October 4, 2004 Chuck Saletta	A Valuation Classic An old-school valuation tool paves a path to market-beating returns.
The Motley Fool February 25, 2011 Todd Wenning	Dividend Report Card: Bristol-Myers Squibb How does the pharma giant's dividend stack up?
The Motley Fool April 28, 2009 Brian Orelli	The Costs of Being Pfizer With Pfizer having announced its intention to buy Wyeth this quarter, investors may have worried that the negotiating and pre-acquisition planning caused management to be distracted, but that doesn't seem to be the case.
The Motley Fool September 12, 2007 James Early	The Stock Screaming "Buy Me!" There is one simple, undeniable factor affecting the long-term equity returns of a stock, and that is whether or not it pays a dividend. Investors, here is a list of seven stocks to consider.
The Motley Fool January 5, 2011 Chuck Saletta	Would Benjamin Graham Approve of These Stocks? We've created the beginnings of a portfolio based on Benjamin Graham's intrinsic value investing criteria.
The Motley Fool August 13, 2010 Ilan Moscovitz	Procter & Gamble: Dividend Dynamo or Disaster? Just how safe is this dividend?
The Motley Fool March 14, 2011 Esterhuizen & Sellitti	Benjamin Graham's Equation: Finding the Most Undervalued High Yield Dividend Stocks One way to determine a stock's value.
The Motley Fool March 4, 2010 Alex Dumortier	These Tech Companies Are Stiffing Shareholders Hoarding cash is no strategy.
The Motley Fool November 13, 2006 Joseph Khattab	A Closer Look at BB&T There's still opportunity in the shares of this regional bank.
Investment Advisor November 2006 Kathleen M. McBride	Equity Income Ingenuity The Goldman Sachs U.S. Equity Dividend and Premium Fund looks to provide a sustainable cash flow for extended lifespans.
The Motley Fool August 3, 2010 Russ Krull	Bond Bubble Brewing Low bond yields make them expensive relative to stocks.
The Motley Fool May 25, 2004 James Early	Present Value for Pretenders The author tackles the basics of discounted cash flow analysis.
The Motley Fool October 22, 2010 Morgan Housel	Bill Miller: These Stocks Could Go 50% Higher Dividend yield could surge without the economy changing a lick if companies just brought payout ratios back to historic averages.
The Motley Fool December 27, 2005	Foolish Fundamentals: Valuation Here's one way to calculate the value of any stock.
The Motley Fool January 9, 2007 Selena Maranjian	How to Earn a 3,017% Return In exchange for his $35 investment in each share of Pfizer stock 47 years ago, this 98-year-old is now receiving $1,056 per share each year. That's some payback, eh?
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
The Motley Fool October 5, 2009 Alex Dumortier	What's Next for Stocks? After the best quarter since 1998, what can you expect, and how should you react?
The Motley Fool October 30, 2009 Brian Orelli	World's Scariest Stocks: Pfizer For Pfizer, the big, scary unknown comes from whether it can integrate its recent acquisition of Wyeth.
The Motley Fool November 30, 2011 Brian Orelli	3 Things More Important to Pfizer Than Losing Lipitor It's not like we didn't see it coming.
The Motley Fool January 19, 2007 Ryan Fuhrmann	The Best Drug Stock for 2007: Pfizer Investors, this is a great company at a great price.
Financial Planning October 1, 2005 Joseph H. Ellis	Choppy Markets Ahead? A look at interest rates, consumer spending and the stock market and how charting them is a significant aid in understanding major stock-market trends for investors and financial advisers alike.
The Motley Fool November 25, 2008 Selena Maranjian	Buffett the Dividend Investor Dividends aren't new to the Oracle of Omaha.
The Motley Fool February 16, 2010 Selena Maranjian	Don't Leave These Big Bucks on the Table! This secret weapon could turbocharge your portfolio. Over the past eight decades, reinvestment of dividends has contributed more than 40% of the S&P 500's return.
The Motley Fool August 23, 2007 Sham Gad	Security Analysis 401: Calculating Intrinsic Value Investors, calculating intrinsic value is simple and straightforward. It's having accurate data that's the difficult part.
The Motley Fool March 27, 2008 Sham Gad	Is This the End for Stocks? As long as you don't overpay, the answer is no. Read on for more.